Last reviewed · How we verify
Beijing Dayspring Pharmaceutical Technology Co., Ltd — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo foam | Placebo foam | marketed | ||||
| minoxidil + finasteride | minoxidil + finasteride | marketed | Combination antialopecia agent | Potassium channels (minoxidil); 5-alpha reductase type II (finasteride) | Dermatology |
Therapeutic area mix
- Dermatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Beijing Dayspring Pharmaceutical Technology Co., Ltd:
- Beijing Dayspring Pharmaceutical Technology Co., Ltd pipeline updates — RSS
- Beijing Dayspring Pharmaceutical Technology Co., Ltd pipeline updates — Atom
- Beijing Dayspring Pharmaceutical Technology Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Beijing Dayspring Pharmaceutical Technology Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-dayspring-pharmaceutical-technology-co-ltd. Accessed 2026-05-16.